Janssen Closer To End-To-End R&D Model With New Research Center In Shanghai
This article was originally published in PharmAsia News
Executive Summary
Janssen has placed a further bet on China R&D by establishing a pharmaceutical discovery laboratory in Shanghai’s Fenglin Life Science Park.
You may also be interested in...
J&J Opens Device R&D Center In China For Growing Rural Market
SHANGHAI - Johnson & Johnson and its device company in China Johnson & Johnson Medical (Suzhou) Ltd. will open a new innovation center in Suzhou to develop medical devices and diagnostic products for emerging markets in Asia
J&J Expands R&D Force In Asia With Opening Of Shanghai R&D Center
SHANGHAI - Johnson & Johnson opened its Asia Pharmaceutical Research and Development Center in Shanghai April 16
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.